PKS Advisory Services LLC Makes New $436,000 Investment in Johnson & Johnson (NYSE:JNJ)

PKS Advisory Services LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 2,834 shares of the company’s stock, valued at approximately $436,000.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. IFS Advisors LLC lifted its position in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares during the last quarter. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson during the fourth quarter worth about $29,000. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson in the fourth quarter worth about $32,000. RPg Family Wealth Advisory LLC bought a new position in shares of Johnson & Johnson during the third quarter valued at approximately $35,000. Finally, Runnymede Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $38,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Morgan Stanley lowered their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 19th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Wells Fargo & Company cut their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Finally, Leerink Partners reduced their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $161.14 on Wednesday. The firm has a market capitalization of $388.32 billion, a PE ratio of 24.23, a PEG ratio of 2.56 and a beta of 0.47. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm’s fifty day simple moving average is $157.70 and its 200 day simple moving average is $156.14.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the previous year, the company posted $2.29 earnings per share. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.08%. Johnson & Johnson’s payout ratio is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.